Immunomodulator therapy in inflammatory bowel disease

  • Peter E. Legnani
  • Asher Kornbluth
Article

Opinion statement

  • 6-Mercaptopurine and its prodrug counterpart, azathioprine, have proven efficacy in the induction and maintenance of remission, fistula closure, and steroid sparing in patients with Crohn’s disease. Long-term follow-up has demonstrated the safety of the purine analogues, with no increased risk of malignancy. For patients with Crohn’s disease intolerant or unresponsive to azathioprine or 6-mercaptopurine, methotrexate has emerged as an effective alternative.

  • In patients with severe ulcerative colitis, intravenous cyclosporine is highly efficacious in the short term, and with the addition of azathioprine or 6-mercaptopurine to oral cyclosporine, long-term remission rates of 60% to 70% can be achieved. Azathioprine or 6-mercaptopurine therapy is effective in patients with steroid-dependent or steroid-refractory colitis and is valuable in maintaining remission. Neither methotrexate nor cyclosporine has been shown to be effective for maintenance therapy in patients with ulcerative colitis.

  • Current data are insufficient to recommend routine use of genetic or enzymatic testing of thiopurine methyltransferase or measurements of blood 6-thioguanine metabolites to guide 6-mercaptopurine or azathioprine dosing.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sandborn W, Sutherland L, Pearson D, et al.: Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. In the Cochrane Library, issue 4 [online database]. Vista, CA: Update Software; 2000. http://www.update-software.com/cochrane/cochrane-frame.html A recent, comprehensive Cochrane review that critically evaluates the controlled trials of azathioprine and 6-mercaptopurine, which concludes that these drugs are effective inducing remission in patients with Crohn’s disease.Google Scholar
  2. 2.
    Sandborn WJ, Tremaine WJ, Wolf DC, et al.: Lack of effect of intravenous administration on time to respond to azathioprine for steroid treated Crohn’s disease: North American Azathioprine Study Group. Gastroenterology 1999, 117:527–535.PubMedCrossRefGoogle Scholar
  3. 3.
    Feagan BG, Ronchon J, Fedorak RN, et al., for the North American Crohn’s Disease Study Group Investigators: Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995, 332:292–297. A double-blind, placebo-controlled trial that reported methotrexate induced remission in 39% of patients with steroid-dependent, chronically active Crohn’s disease, compared with 19% for placebo.PubMedCrossRefGoogle Scholar
  4. 4.
    Chong RY, Hanauer SB, Cohen RD: Efficacy of parenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther 2001, 15:35–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Feagan BG, McDonald JWD, Rochon J, et al., For the Canadian Crohn’s relapse prevention trial investigators. Low dose cyclosporin for the treatment of Crohn’s disease. N Engl J Med 1994, 330:1846–1851.PubMedCrossRefGoogle Scholar
  6. 6.
    Jewell DP, Lennard-Jones JE, and the Cyclosporin Study Group of Great Britain and Ireland: Oral cyclosporin for chronic active Crohn’s disease: a multicenter controlled trial. Eur J Gastroenterol Hepatol 1994, 6:499–505.CrossRefGoogle Scholar
  7. 7.
    Stange EF, Modigliani R, Penna AS, et al., and the European Study Group: European trial of cyclosporin in chronic active Crohn’s disease: a 12 month study. Gastroenterology 1995, 109:774–782.PubMedCrossRefGoogle Scholar
  8. 8.
    Brynskov J, Freund L, Rasmussen SM, et al.: A placebocontrolled, double-blind, randomized controlled trial of cyclosporin therapy in active Crohn’s disease. N Engl J Med 1989, 321:845–850.PubMedCrossRefGoogle Scholar
  9. 9.
    Egan LJ, Sandborn WJ, Tremaine WJ: Clinical outcome following treatment for refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporin. Am J Gastroenterol 1998, 93:442–448.PubMedCrossRefGoogle Scholar
  10. 10.
    Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn’s disease. In the Cochrane Library, issue 4 [online database]. Vista, CA: Update Software; 2000. http://www.updatesoftware. com/cochrane/cochrane-frame.html A comprehensive review from the Cochrane collection that rigorously evaluates the controlled trials of azathioprine, and concludes that azathioprine is effective for maintenance of remission in patients with Crohn’s disease.Google Scholar
  11. 11.
    Korelitz BI, Mirsky FJ, Fleisher MR, et al.: Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999, 94:3254–3257.PubMedCrossRefGoogle Scholar
  12. 12.
    Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000, 342:1627–1632. A double-blind, placebo-controlled study in patients who had methotrexate-induced remission of Crohn’s disease that demonstrated that 65% of patients are able to sustain remission using low-dosage methotrexate.PubMedCrossRefGoogle Scholar
  13. 13.
    Lemann M, Zenjari T, Bouhnik Y, et al.: Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95:1730–1734.PubMedGoogle Scholar
  14. 14.
    Lobo AJ, Juby LD, Rothwell J, et al.: Long-term treatment of Crohn’s disease with cyclosporin: the effect of a very low dose on the maintenance of remission. J Clin Gastroenterol 1991, 13:42–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Korelitz B, Hanauer S, Rutgeerts P, et al.: Postoperative prophylaxis with 6-MP, 5-ASA, or placebo in Crohn’s disease: a two year multicenter trial [abstract]. Gastroenterology 1998, 114:A1011.CrossRefGoogle Scholar
  16. 16.
    Lemann M, Cuillerier E, Bouhnik Y, et al.: Azathioprine for prevention of Crohn’s recurrence after ileal or colonic resection [abstract]. Gastroenterology 1996, 110:A948.Google Scholar
  17. 17.
    Korelitz BI, Adler DJ, Mendelsohn RA, et al.: Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993, 88:1198–1205.PubMedGoogle Scholar
  18. 18.
    Korelitz BI, Present DH: Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 1985, 30:58–64.PubMedCrossRefGoogle Scholar
  19. 19.
    Hanauer SB, Smith MB: Rapid closure of Crohn’s disease fistulas with intravenous cyclosporin A. Am J Gastroenterol 1993, 88:646–664.PubMedGoogle Scholar
  20. 20.
    Present DH, Lichtiger S: Efficacy of cyclosporin in treatment of fistula in Crohn’s disease. Dig Dis Sci 1994, 39:374–380.PubMedCrossRefGoogle Scholar
  21. 21.
    Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000, 6:48–57. A comprehensive article that reviews the significant side effects of chronic corticosteroid use and the expanding array of therapeutic alternative drugs for patients with Crohn’s disease or ulcerative colitis.PubMedCrossRefGoogle Scholar
  22. 22.
    Mahadevan U, Tremaine WJ, Johnson T, et al.: Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 2000, 95:3463–3468.PubMedCrossRefGoogle Scholar
  23. 23.
    Oren R, Arber N, Odes S, et al.: Methotrexate for chronic ulcerative colitis: a double blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110:1416–1421.PubMedCrossRefGoogle Scholar
  24. 24.
    Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845. A randomized, double-blind, placebo-controlled trial that demonstrated an 83% success rate of intravenous cyclosporin in patients with severe ulcerative colitis.PubMedCrossRefGoogle Scholar
  25. 25.
    Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporine in ulcerative colitis: a five year experience. Am J Gastroenterol 1999, 94:1587–1592. This report highlights the importance of giving azathioprine or 6-mercaptopurine patients who respond to cyclosporin.PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen RD, Brodsky AL, Hanauer SB: A comparison of quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999, 5:1–10.PubMedCrossRefGoogle Scholar
  27. 27.
    George JG, Present DH, Pou R, et al.: The long term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996, 91:1711–1714.PubMedGoogle Scholar
  28. 28.
    Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32:651–662.PubMedGoogle Scholar
  29. 29.
    Colombel JF, Ferrari N, Debuysere H, et al.: Genotypic analysis of thiopurine-S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118:1025–1030.PubMedCrossRefGoogle Scholar
  30. 30.
    Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705–713.PubMedCrossRefGoogle Scholar
  31. 31.
    Kremer JM, Alarcon GS, Lightfoot RW, et al.: Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994, 37:316–328.PubMedCrossRefGoogle Scholar
  32. 32.
    Te HS, Schiano TS, Kuan SF, et al.: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150–3156.PubMedCrossRefGoogle Scholar
  33. 33.
    Kornbluth A, Present DH, Lichtiger S, Hanauer SB: Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol 1997, 92:1424–1428. A practical guide for the clinician detailing the authors’ approach to prescribing and monitoring therapy with cyclosporin.PubMedGoogle Scholar
  34. 34.
    Kozarek JM, Meller EA, Johnston A, et al.: Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporin formulation. Pharmacotherapy 1993, 13:613–617.Google Scholar
  35. 35.
    Sternthal M, George J, Kornbluth A, et al.: Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease. Gastroenterology 1996, 110:A1019.Google Scholar
  36. 36.
    Judge TA, Lichtenstein GR: Refractory inflammatory bowel disease. Curr Treat Opt Gastroenterol 2001, 4:267–273.Google Scholar
  37. 37.
    Farrell RJ, Ang Y, Kileen P, et al.: Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk appears low. Gut 2000, 47:514–519.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Peter E. Legnani
    • 1
  • Asher Kornbluth
    • 1
  1. 1.The Dr. Henry D. Janowitz Division of Gastroenterology, Department of MedicineThe Mount Sinai School of MedicineNew YorkUSA

Personalised recommendations